索拉非尼标准治疗后靶向免疫抑制以促进肝细胞癌的免疫检查点阻断——关于临床潜力和未来发展的自我评论
Targeting immunosuppression after standard sorafenib treatment to facilitate immune checkpoint blockade in hepatocellular carcinoma - an auto-commentary on clinical potential and future development.
作者信息
Chen Yunching, Duda Dan G
机构信息
Institute of Biomedical Engineering; National Tsing Hua University ; Hsinchu, Taiwan ; Steele Laboratories for Tumor Biology; Department of Radiation Oncology; Massachusetts General Hospital and Harvard Medical School ; Boston, MA USA.
Steele Laboratories for Tumor Biology; Department of Radiation Oncology; Massachusetts General Hospital and Harvard Medical School ; Boston, MA USA.
出版信息
Oncoimmunology. 2015 May 27;4(10):e1029703. doi: 10.1080/2162402X.2015.1029703. eCollection 2015 Oct.
Abstract
Immunotherapy has shown great promise to transform solid cancer treatment. The challenge is to optimally incorporate novel immunotherapeutics, such as immune checkpoint blockers, with standard therapies. This is well exemplified by multimodal therapies recently developed for liver cancer in which immunomodulation using CXCR4 inhibition prevented immunosuppression and enhanced sorafenib and anti-PD-1 therapeutic outcome.
摘要
免疫疗法已显示出在改变实体癌治疗方面的巨大前景。挑战在于如何将新型免疫疗法（如免疫检查点阻断剂）与标准疗法进行最佳整合。最近为肝癌开发的多模式疗法很好地例证了这一点，其中使用CXCR4抑制进行免疫调节可防止免疫抑制，并增强索拉非尼和抗PD - 1的治疗效果。
相似文献
1
Targeting immunosuppression after standard sorafenib treatment to facilitate immune checkpoint blockade in hepatocellular carcinoma - an auto-commentary on clinical potential and future development.索拉非尼标准治疗后靶向免疫抑制以促进肝细胞癌的免疫检查点阻断——关于临床潜力和未来发展的自我评论
Oncoimmunology. 2015 May 27;4(10):e1029703. doi: 10.1080/2162402X.2015.1029703. eCollection 2015 Oct.
2
CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice.肿瘤微环境中的CXCR4抑制可促进索拉非尼治疗的小鼠肝细胞癌中的抗程序性死亡受体-1免疫治疗。
Hepatology. 2015 May;61(5):1591-602. doi: 10.1002/hep.27665. Epub 2015 Mar 20.
3
Treatment of advanced hepatocellular carcinoma: immunotherapy from checkpoint blockade to potential of cellular treatment.晚期肝细胞癌的治疗：从免疫检查点阻断到细胞治疗潜力的免疫疗法
Transl Gastroenterol Hepatol. 2018 Nov 7;3:89. doi: 10.21037/tgh.2018.10.16. eCollection 2018.
4
Immune checkpoint therapy in liver cancer.肝癌的免疫检查点治疗。
J Exp Clin Cancer Res. 2018 May 29;37(1):110. doi: 10.1186/s13046-018-0777-4.
5
Can Combined Therapy Benefit Immune Checkpoint Blockade Response in Hepatocellular Carcinoma?联合治疗能否改善肝癌的免疫检查点阻断反应？
Anticancer Agents Med Chem. 2019;19(2):222-228. doi: 10.2174/1871520618666181114112431.
6
Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma.晚期肝细胞癌的分子靶向和免疫检查点治疗。
J Exp Clin Cancer Res. 2019 Nov 4;38(1):447. doi: 10.1186/s13046-019-1412-8.
7
Immune Checkpoint Blockade in Breast Cancer Therapy.免疫检查点阻断在乳腺癌治疗中的应用。
Adv Exp Med Biol. 2017;1026:383-402. doi: 10.1007/978-981-10-6020-5_18.
8
Blocking CXCR4 alleviates desmoplasia, increases T-lymphocyte infiltration, and improves immunotherapy in metastatic breast cancer.阻断 CXCR4 可减轻肿瘤基质纤维化，增加 T 淋巴细胞浸润，改善转移性乳腺癌的免疫治疗效果。
Proc Natl Acad Sci U S A. 2019 Mar 5;116(10):4558-4566. doi: 10.1073/pnas.1815515116. Epub 2019 Jan 30.
9
Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib.载sorafenib 和米非司酮的 CXCR4 靶向 PLGA-PEG 纳米粒共递送克服了肝细胞癌对 sorafenib 的耐药性。
J Exp Clin Cancer Res. 2019 May 31;38(1):232. doi: 10.1186/s13046-019-1216-x.
10
The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.下一代免疫检查点抑制剂：黑色素瘤中的PD-1/PD-L1阻断
Clin Ther. 2015 Apr 1;37(4):764-82. doi: 10.1016/j.clinthera.2015.02.018. Epub 2015 Mar 29.
引用本文的文献
1
Synergistic anti-tumour activity of sorafenib in combination with pegylated resveratrol is mediated by Akt/mTOR/p70S6k-4EBP-1 and c-Raf7MEK/ERK signaling pathways.索拉非尼与聚乙二醇化白藜芦醇联合使用时的协同抗肿瘤活性是由Akt/mTOR/p70S6k-4EBP-1和c-Raf/MEK/ERK信号通路介导的。
Heliyon. 2023 Aug 19;9(8):e19154. doi: 10.1016/j.heliyon.2023.e19154. eCollection 2023 Aug.
2
The effects of Sorafenib and Natural killer cell co-injection in combinational treatment of hepatocellular carcinoma; an in vivo approach.索拉非尼和自然杀伤细胞共注射联合治疗肝细胞癌的效果：体内研究。
Pharmacol Rep. 2022 Apr;74(2):379-391. doi: 10.1007/s43440-021-00335-y. Epub 2022 Jan 28.
3
Combinational immune-cell therapy of natural killer cells and sorafenib for advanced hepatocellular carcinoma: a review.自然杀伤细胞与索拉非尼联合免疫细胞疗法治疗晚期肝细胞癌：综述
Cancer Cell Int. 2018 Sep 10;18:133. doi: 10.1186/s12935-018-0624-x. eCollection 2018.
4
Sorafenib paradoxically activates the RAS/RAF/ERK pathway in polyclonal human NK cells during expansion and thereby enhances effector functions in a dose- and time-dependent manner.索拉非尼在扩增过程中反常地激活多克隆人 NK 细胞中的 RAS/RAF/ERK 通路，从而以剂量和时间依赖的方式增强效应功能。
Clin Exp Immunol. 2018 Jul;193(1):64-72. doi: 10.1111/cei.13128. Epub 2018 May 7.
5
Overcoming sorafenib evasion in hepatocellular carcinoma using CXCR4-targeted nanoparticles to co-deliver MEK-inhibitors.利用 CXCR4 靶向纳米粒共递送 MEK 抑制剂克服肝细胞癌对索拉非尼的逃逸
Sci Rep. 2017 Mar 9;7:44123. doi: 10.1038/srep44123.
本文引用的文献
1
CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice.肿瘤微环境中的CXCR4抑制可促进索拉非尼治疗的小鼠肝细胞癌中的抗程序性死亡受体-1免疫治疗。
Hepatology. 2015 May;61(5):1591-602. doi: 10.1002/hep.27665. Epub 2015 Mar 20.
2
Immune checkpoint blockade in hepatocellular carcinoma: current progress and future directions.肝细胞癌中的免疫检查点阻断：当前进展与未来方向
Hepatology. 2014 Nov;60(5):1776-82. doi: 10.1002/hep.27246. Epub 2014 Sep 26.
3
Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1 alpha/C-X-C receptor type 4 axis and myeloid differentiation antigen-positive myeloid cell infiltration in mice.索拉非尼通过基质衍生因子 1 ɑ/C-X-C 受体型 4 轴和骨髓分化抗原阳性髓样细胞浸润对肝与肿瘤纤维化的差异作用及其在小鼠中的机制。
Hepatology. 2014 Apr;59(4):1435-47. doi: 10.1002/hep.26790. Epub 2014 Feb 18.
4
Deciphering and reversing tumor immune suppression.解析并逆转肿瘤免疫抑制。
Immunity. 2013 Jul 25;39(1):61-73. doi: 10.1016/j.immuni.2013.07.005.
5
Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers.将肿瘤微环境正常化以治疗癌症：从实验室到临床再到生物标志物。
J Clin Oncol. 2013 Jun 10;31(17):2205-18. doi: 10.1200/JCO.2012.46.3653. Epub 2013 May 13.
6
Vascular normalization as an emerging strategy to enhance cancer immunotherapy.血管正常化作为一种新兴的策略，以增强癌症免疫治疗。
Cancer Res. 2013 May 15;73(10):2943-8. doi: 10.1158/0008-5472.CAN-12-4354. Epub 2013 Feb 25.
7
Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy.抗血管生成治疗的血管正常化剂量可重新编程免疫抑制性肿瘤微环境并增强免疫治疗。
Proc Natl Acad Sci U S A. 2012 Oct 23;109(43):17561-6. doi: 10.1073/pnas.1215397109. Epub 2012 Oct 8.
8
Novel cancer immunotherapy agents with survival benefit: recent successes and next steps.具有生存获益的新型癌症免疫治疗药物：近期的成功和下一步措施。
Nat Rev Cancer. 2011 Oct 24;11(11):805-12. doi: 10.1038/nrc3153.
9
Targeting hypoxia in cancer therapy.针对癌症治疗中的缺氧。
Nat Rev Cancer. 2011 Jun;11(6):393-410. doi: 10.1038/nrc3064.
10
Sorafenib in advanced hepatocellular carcinoma.索拉非尼用于晚期肝细胞癌
N Engl J Med. 2008 Jul 24;359(4):378-90. doi: 10.1056/NEJMoa0708857.
Zotero 插件